As of 2020, approximately 5.8 million Americans suffer from Alzheimer’s disease, but recent groundbreaking research may provide hope to better understand and potentially prevent this devastating condition.
Sarepta’s gene therapy to be manufactured at Catalent plant with ‘operational challenges’ this spring
Catalent, the contract manufacturer in the process of overhauling its operations, is manufacturing Sarepta Therapeutics’ newly approved gene therapy for Duchenne muscular dystrophy at one